Lead Product(s): 8-Chloro-N-(4-(trifluoromethoxy)phenyl)quinolin-2-amine
Therapeutic Area: Gastroenterology Product Name: ABX464
Highest Development Status: Phase II Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 02, 2020
Phase 2a open label maintenance results after second year of treatment confirm good safety profile and durable efficacy of 50mg once-daily oral ABX464.